Monitor for FDA submission progress and CMS reimbursement decisions for OneTest. Near-term stock movement is unlikely from this routine investor presentation. The company's tiny market cap ($7M) means any regulatory catalyst could produce outsized moves, but no such catalyst is imminent based on this filing.
Price Chart
Executive Summary
20/20 Biolabs, Inc. filed an 8-K furnishing an investor presentation used in a July 1, 2026 webinar. The presentation outlines the company's 'OneTest' multi-cancer early detection test, discusses a recently passed MCED Medicare reimbursement pathway (effective 2028), and provides forward-looking revenue projections based on a hypothetical 5% royalty pool of ~$100 million. No current financial results were disclosed, and the filing is a routine Regulation FD disclosure with no material new financial data.
Key Facts
- Filed investor presentation for July 1, 2026 webinar; no financial results reported.
- Presentation cites the Multi-Cancer Early Detection Screening Coverage Act (signed Feb. 3, 2026) as a catalyst for Medicare reimbursement of MCED tests starting in 2028.
- OneTest is currently offered as an LDT without FDA De Novo authorization or PMA approval; Medicare coverage requires FDA authorization and CMS determination it is clinically appropriate.
- Presentation includes hypothetical revenue projections modeled as a 5% royalty pool on revenues over the first 5 years, described as ~$100 million, based on a single-company analogy (Exact Sciences / Cologuard).
- Describes M&A strategy targeting bolt-on acquisitions of companies with $2M–$8M in annualized revenues, mostly stock transactions.
- Market cap ~$7M; Nasdaq-listed with minimal institutional ownership.
Financial Impact
Projected ~$100 million royalty pool over 5 years (purely hypothetical, based on FDA approval and CMS reimbursement assumptions); no actual revenue reported.
Risk Factors
- OneTest has not received FDA authorization; no assurance it will obtain FDA or CMS approval.
- Revenue projections are hypothetical and based on a single-company analogy (Cologuard) that may not be predictive.
- Grail's Galleri trial missed primary endpoint, but competitor risk remains.
- Company is pre-revenue with a $7M market cap; low liquidity and high dilution risk.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-074182 |
| Document: ea0296736-8k_2020bio.htm | 0001213900-26-074182 |
| Document: 0001213900-26-074182-index-headers.html | 0001213900-26-074182 |
| Document: 0001213900-26-074182-index.html | 0001213900-26-074182 |
| Document: 0001213900-26-074182.txt | 0001213900-26-074182 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | DEFA14A | $0.2507 | awaiting T+5 | — | $0.2325 (−7.26%) |
Oct 21, 2026 5d ago | DEF 14A | $0.2507 | awaiting T+5 | — | $0.2325 (−7.26%) |
Aug 17, 2026 10w ago | 8-K | $0.5200 $0.5282 | ▲ +1.58% | ▲ +1.78% | $0.2325 (−55.29%) |
Aug 17, 2026 10w ago | Press Release | $0.5503 $0.5182 | ▼ −5.83% | ▼ −4.64% | $0.2325 (−57.75%) |
Aug 5, 2026 11w ago | 8-K | $0.4413 $0.4610 | ▲ +4.46% | ▲ +4.11% | $0.2325 (−47.31%) |
Jul 1, 2026 16w ago | 8-K | $0.6095 $0.5851 | ▼ −4.00% | ▼ −4.26% | $0.2325 (−61.85%) |
Jun 23, 2026 17w ago | DEFA14A | $0.5669 $0.6095 | ▼ −7.51% | ▼ −5.81% | $0.2325 (+58.99%) |
May 26, 2026 21w ago | 8-K | $0.9700 $0.8400 | ▼ −13.40% | ▼ −13.87% | $0.2325 (−76.03%) |
May 20, 2026 22w ago | 8-K | $1.21 $0.9500 | ▲ +21.49% | ▲ +23.09% | $0.2325 (+80.79%) |
May 20, 2026 22w ago | Press Release | $1.21 $0.9500 | ▲ +21.49% | ▲ +23.09% | $0.2325 (+80.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers